Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Stopped A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.

Conditions

• Multiple Myeloma

Interventions

• DRUG: Oprozomib
• DRUG: Lenalidomide
• DRUG: Dexamethasone
• DRUG: Cyclophosphamide

Sponsor

Amgen